| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
|
Lancet
|
2006
|
12.98
|
|
2
|
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.
|
Lancet
|
2004
|
11.37
|
|
3
|
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.
|
Lancet
|
2012
|
8.00
|
|
4
|
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
|
Lancet
|
2012
|
5.62
|
|
5
|
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.
|
Eur J Cancer
|
2006
|
4.92
|
|
6
|
A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.
|
Gastroenterology
|
2004
|
3.61
|
|
7
|
Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.
|
Lancet Oncol
|
2007
|
3.38
|
|
8
|
Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution.
|
Cancer
|
2006
|
2.98
|
|
9
|
Rare cancers are not so rare: the rare cancer burden in Europe.
|
Eur J Cancer
|
2011
|
2.95
|
|
10
|
Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.
|
J Clin Oncol
|
2005
|
2.68
|
|
11
|
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.
|
Eur J Cancer
|
2005
|
2.54
|
|
12
|
Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment.
|
Ann Surg Oncol
|
2009
|
2.48
|
|
13
|
Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution.
|
Cancer
|
2004
|
2.46
|
|
14
|
Role of macrophage targeting in the antitumor activity of trabectedin.
|
Cancer Cell
|
2013
|
2.35
|
|
15
|
Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution.
|
Cancer
|
2003
|
2.11
|
|
16
|
Extremity soft tissue sarcoma: adding to the prognostic meaning of local failure.
|
Ann Surg Oncol
|
2007
|
1.76
|
|
17
|
Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells.
|
Cancer Res
|
2010
|
1.68
|
|
18
|
Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution.
|
Cancer
|
2004
|
1.61
|
|
19
|
A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.
|
Eur J Cancer
|
2012
|
1.57
|
|
20
|
A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake.
|
J Clin Endocrinol Metab
|
2007
|
1.47
|
|
21
|
Translocation-related sarcomas.
|
Semin Oncol
|
2009
|
1.45
|
|
22
|
Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system.
|
Cancer
|
2005
|
1.45
|
|
23
|
Response to sunitinib malate in advanced alveolar soft part sarcoma.
|
Clin Cancer Res
|
2009
|
1.39
|
|
24
|
Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005.
|
Eur J Cancer
|
2007
|
1.38
|
|
25
|
A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.
|
Clin Cancer Res
|
2009
|
1.37
|
|
26
|
Molecular and biochemical analyses of platelet-derived growth factor receptor (PDGFR) B, PDGFRA, and KIT receptors in chordomas.
|
Clin Cancer Res
|
2006
|
1.35
|
|
27
|
Dermatofibrosarcoma protuberans treated at a single institution: a surgical disease with a high cure rate.
|
J Clin Oncol
|
2005
|
1.32
|
|
28
|
Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response.
|
Mol Cancer Ther
|
2010
|
1.29
|
|
29
|
Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience.
|
Ann Surg Oncol
|
2013
|
1.28
|
|
30
|
Myxoid/round cell and pleomorphic liposarcomas: prognostic factors and survival in a series of patients treated at a single institution.
|
Cancer
|
2007
|
1.27
|
|
31
|
Prognostic effect of re-excision in adult soft tissue sarcoma of the extremity.
|
Ann Surg Oncol
|
2006
|
1.27
|
|
32
|
Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.
|
Clin Cancer Res
|
2012
|
1.25
|
|
33
|
Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG).
|
Eur J Cancer
|
2006
|
1.24
|
|
34
|
Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.
|
J Clin Oncol
|
2009
|
1.23
|
|
35
|
Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size.
|
Am J Surg Pathol
|
2010
|
1.21
|
|
36
|
The prognostic impact of dedifferentiation in retroperitoneal liposarcoma: a series of surgically treated patients at a single institution.
|
Cancer
|
2008
|
1.15
|
|
37
|
Natural history of imatinib-naive GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables.
|
Am J Surg Pathol
|
2011
|
1.12
|
|
38
|
Epithelioid sarcoma: prognostic factors and survival in a series of patients treated at a single institution.
|
Ann Surg Oncol
|
2007
|
1.11
|
|
39
|
Surgical technique, morbidity, and outcome of primary retroperitoneal sarcoma involving inferior vena cava.
|
Ann Surg Oncol
|
2011
|
1.11
|
|
40
|
Postoperative radiotherapy for synovial sarcoma of the head and neck during pregnancy: clinical and technical management and fetal dose estimates.
|
Tumori
|
2007
|
1.09
|
|
41
|
Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution.
|
Ann Surg Oncol
|
2010
|
1.09
|
|
42
|
Expression of ligand-activated KIT and platelet-derived growth factor receptor beta tyrosine kinase receptors in synovial sarcoma.
|
Clin Cancer Res
|
2004
|
1.08
|
|
43
|
Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib.
|
Int J Cancer
|
2011
|
1.08
|
|
44
|
Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas.
|
Neuro Oncol
|
2010
|
1.04
|
|
45
|
Desmoid-type fibromatosis and pregnancy: a multi-institutional analysis of recurrence and obstetric risk.
|
Ann Surg
|
2014
|
1.03
|
|
46
|
c-Kit/PDGFRA gene status alterations possibly related to primary imatinib resistance in gastrointestinal stromal tumors.
|
Clin Cancer Res
|
2007
|
1.01
|
|
47
|
Alveolar soft part sarcoma: clinical presentation, treatment, and outcome in a series of 33 patients at a single institution.
|
Ann Surg Oncol
|
2010
|
1.00
|
|
48
|
Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network.
|
Anticancer Drugs
|
2015
|
0.95
|
|
49
|
Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy.
|
Cancer
|
2012
|
0.94
|
|
50
|
Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib.
|
Clin Sarcoma Res
|
2013
|
0.91
|
|
51
|
Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy.
|
Pharmacol Res
|
2012
|
0.91
|
|
52
|
Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study.
|
Clin Sarcoma Res
|
2013
|
0.91
|
|
53
|
Adjuvant treatment of GIST with imatinib: solid ground or still quicksand? A comment on behalf of the EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group and the Spanish Sarcoma Group (GEIS).
|
Eur J Cancer
|
2009
|
0.89
|
|
54
|
Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib.
|
Clin Sarcoma Res
|
2012
|
0.89
|
|
55
|
Emerging therapies for adult soft tissue sarcoma.
|
Expert Rev Anticancer Ther
|
2014
|
0.88
|
|
56
|
A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet-derived growth factor receptor-α or -β: An Italian Sarcoma Group study.
|
Cancer
|
2010
|
0.88
|
|
57
|
Sacral Chordoma: Long-term Outcome of a Large Series of Patients Surgically Treated at Two Reference Centers.
|
Spine (Phila Pa 1976)
|
2016
|
0.87
|
|
58
|
Targeted therapies in rare sarcomas: IMT, ASPS, SFT, PEComa, and CCS.
|
Hematol Oncol Clin North Am
|
2013
|
0.85
|
|
59
|
The intriguing patterns of tumor response to trabectedin.
|
Expert Rev Anticancer Ther
|
2013
|
0.85
|
|
60
|
KIT, PDGFRA, and BRAF mutational spectrum impacts on the natural history of imatinib-naive localized GIST: a population-based study.
|
Am J Surg Pathol
|
2015
|
0.82
|
|
61
|
Personalizing the approach to retroperitoneal soft tissue sarcoma: histology-specific patterns of failure and postrelapse outcome after primary extended resection.
|
Ann Surg Oncol
|
2014
|
0.82
|
|
62
|
Is autophagy rather than apoptosis the regression driver in imatinib-treated gastrointestinal stromal tumors?
|
Transl Oncol
|
2008
|
0.82
|
|
63
|
Receptor tyrosine kinase pathway analysis sheds light on similarities between clear-cell sarcoma and metastatic melanoma.
|
Genes Chromosomes Cancer
|
2011
|
0.82
|
|
64
|
Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution.
|
Ann Surg Oncol
|
2006
|
0.82
|
|
65
|
Myogenic differentiation and histologic grading are major prognostic determinants in retroperitoneal liposarcoma.
|
Am J Surg Pathol
|
2015
|
0.82
|
|
66
|
Postoperative Morbidity After Radical Resection of Primary Retroperitoneal Sarcoma: A Report From the Transatlantic RPS Working Group.
|
Ann Surg
|
2017
|
0.82
|
|
67
|
Myxoid liposarcoma and the mammalian target of rapamycin pathway.
|
Curr Opin Oncol
|
2013
|
0.81
|
|
68
|
Ewing sarcoma of the small bowel: a study of seven cases, including one with the uncommonly reported EWSR1-FEV translocation.
|
Histopathology
|
2014
|
0.81
|
|
69
|
Resection of uninvolved adjacent organs can be part of surgery for retroperitoneal soft tissue sarcoma.
|
J Clin Oncol
|
2009
|
0.81
|
|
70
|
Localised thoracic sarcomas: outcome improvement over time at a single institution.
|
Eur J Cancer
|
2013
|
0.81
|
|
71
|
MRP1 overexpression determines poor prognosis in prospectively treated patients with localized high-risk soft tissue sarcoma of limbs and trunk wall: an ISG/GEIS study.
|
Mol Cancer Ther
|
2013
|
0.78
|
|
72
|
Management of Gastrointestinal Stromal Tumour: Current Practices and Visions for the Future.
|
Oncology
|
2015
|
0.77
|
|
73
|
Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations: an imaging, biochemical and molecular modeling study.
|
Int J Cancer
|
2011
|
0.77
|
|
74
|
Adjuvant therapy for high-risk soft tissue sarcoma in the adult.
|
Curr Treat Options Oncol
|
2013
|
0.76
|
|
75
|
Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working Group.
|
Ann Surg
|
2016
|
0.76
|
|
76
|
Improving methodology to go beyond histology in rare cancers.
|
Lancet Oncol
|
2013
|
0.75
|
|
77
|
Hope in cancer patients: the relational domain as a crucial factor.
|
Tumori
|
2015
|
0.75
|
|
78
|
Gastrointestinal stromal tumors: should they be treated with the same systemic chemotherapy as other soft tissue sarcomas?
|
Oncology
|
2003
|
0.75
|
|
79
|
Fluorescence in situ hybridization analysis and immunophenotyping of c-Kit/PDGFRA and Bcl-2 expression in gastrointestinal stromal tumors.
|
Anal Quant Cytol Histol
|
2010
|
0.75
|
|
80
|
A new journal... on spindle cells.
|
Clin Sarcoma Res
|
2011
|
0.75
|
|
81
|
Do rare cancers deserve specific strategies for cancer research?
|
Lancet Oncol
|
2010
|
0.75
|
|
82
|
Neoadjuvant treatment: a novel standard?
|
Curr Opin Oncol
|
2017
|
0.75
|
|
83
|
Leiomyosarcoma and sarcoma with myogenic differentiation: two different entities or 2 faces of the same disease?
|
Cancer
|
2012
|
0.75
|